- Home
- OPEN vs ETNB Comparison
OPEN vs ETNB Comparison
Compare OPEN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPEN
- ETNB
- Stock Information
- Founded
- OPEN 2014
- ETNB 2018
- Country
- OPEN United States
- ETNB United States
- Employees
- OPEN N/A
- ETNB N/A
- Industry
- OPEN Real Estate
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- OPEN Finance
- ETNB Health Care
- Exchange
- OPEN Nasdaq
- ETNB Nasdaq
- Market Cap
- OPEN 1.4B
- ETNB 1.5B
- IPO Year
- OPEN N/A
- ETNB 2019
- Fundamental
- Price
- OPEN $4.02
- ETNB $9.34
- Analyst Decision
- OPEN Sell
- ETNB Strong Buy
- Analyst Count
- OPEN 4
- ETNB 9
- Target Price
- OPEN $1.45
- ETNB $26.63
- AVG Volume (30 Days)
- OPEN 292.5M
- ETNB 1.5M
- Earning Date
- OPEN 08-05-2025
- ETNB 08-07-2025
- Dividend Yield
- OPEN N/A
- ETNB N/A
- EPS Growth
- OPEN N/A
- ETNB N/A
- EPS
- OPEN N/A
- ETNB N/A
- Revenue
- OPEN $5,181,000,000.00
- ETNB N/A
- Revenue This Year
- OPEN N/A
- ETNB N/A
- Revenue Next Year
- OPEN $18.95
- ETNB N/A
- P/E Ratio
- OPEN N/A
- ETNB N/A
- Revenue Growth
- OPEN 14.07
- ETNB N/A
- 52 Week Low
- OPEN $0.51
- ETNB $4.16
- 52 Week High
- OPEN $5.87
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- OPEN 60.75
- ETNB 49.00
- Support Level
- OPEN $3.06
- ETNB $9.07
- Resistance Level
- OPEN $5.87
- ETNB $9.70
- Average True Range (ATR)
- OPEN 0.71
- ETNB 0.46
- MACD
- OPEN 0.12
- ETNB 0.05
- Stochastic Oscillator
- OPEN 54.88
- ETNB 71.85
About OPEN Opendoor Technologies Inc
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).